Brock University Lung Cancer Malignancy Score
Predicts malignancy probability in pulmonary nodules found on CT screening. Validated for nodules 6–30 mm. Used alongside Fleischner and BTS guidelines.
Score interpretation
Low malignancy probability — routine screening interval appropriate
→ Routine follow-up per Fleischner/BTS guidelines; no urgent action required
Intermediate malignancy probability (1.5–10%)
→ CT follow-up at 3–6 months to assess growth; discussion at MDT
High malignancy probability >10%
→ Urgent MDT discussion; PET-CT; bronchoscopy or CT-guided biopsy; early surgical or oncological referral
Interpretation bands for the Brock Score. Apply clinical judgement and local guidance.
References
- McWilliams A et al. Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med. 2013;369(10):910–919.
Related
Curated clinical cross-links plus same-class fallbacks.
- Nitric Oxide (Inhaled — iNO) · Selective Pulmonary Vasodilator
- Selexipag · Pulmonary Arterial Hypertension
- Macitentan · Pulmonary Arterial Hypertension
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Cisplatin · Platinum Chemotherapy — Head and Neck Cancer
- Betamethasone (Antenatal Corticosteroids) · Corticosteroid (Fetal Lung Maturation)
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.